CoChat

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly

Open access
Vink, Peter, Shiramoto, Masanari, Ogawa, Masayuki, Eda, Masahiro, Douha, Martine, Heineman, Thomas, Lal, Himal · 2017 · Human Vaccines & Immunotherapeutics

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

The impact of alternate routes of vaccine administration, subcutaneous (SC) or intramuscular (IM), on the safety and immunogenicity of herpes zoster subunit candidate vaccine (HZ/su) was assessed in Japanese adults aged ≥ 50 y. During this phase III open-label study, 60 subjects were randomized (1:1) to receive HZ/su through SC or IM routes in a 0, 2 month schedule. Vaccine response rates (VRRs) and geometric mean concentrations (GMCs) of varicella zoster virus glycoprotein E (gE)-specific antibodies were determined by ELISA. Solicited and unsolicited symptoms were recorded for 7 and 30 d after each vaccination and graded 1-3 in severity. Serious adverse events (SAEs) were recorded throughout the study. At one month post-dose 2, VRRs were 100% (95% Confidence Interval (CI): 88.1-100) in both groups; anti-gE antibody GMCs were 44126.1 mIU/ml (95% CI: 36326.1-53601.0) and 45521.5 mIU/ml (95% CI; 37549.5-55185.9) in the SC and IM groups, respectively. Injection site reactions (pain, swelling and redness) were common, and observed more frequently following SC administration. Grade 3 redness and swelling were more frequently observed after SC administration. Fatigue and headache were the most frequently reported general symptoms for both routes of administration. Ten and 7 unsolicited AEs were reported in the SC and IM group, respectively. Two unsolicited AEs (1 in SC; 1 in IM) were considered related to vaccination by the investigator. Three non-fatal SAEs considered unrelated to vaccination were reported during the study. Administration of the HZ/su vaccine candidate resulted in a substantial immune response that was comparable between SC and IM subjects, but local reactogenicity may be greater for SC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2016.1232787

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Disposition of study participants. SC: Subcutaneous IM: Intramuscular.
Figure 1. Disposition of study participants. SC: Subcutaneous IM: Intramuscular.CC BY · PubMed Central
Figure 2. Vaccine response rate and geometric mean concentrations of anti-gE antibody (ATP cohort for immunogenicity). Samples were collected at the indicated time points (for both subcutaneous (SC) versus intramuscular (IM) groups) and anti-gE antibody concentrations were determined by ELISA. Data are vaccine response rates (VRRs) and geometric mean concentrations (GMCs) and error bars indicate 95% confidence interval.
Figure 2. Vaccine response rate and geometric mean concentrations of anti-gE antibody (ATP cohort for immunogenicity). Samples were collected at the indicated time points (for both subcutaneous (SC) versus intramuscular (IM) groups) and anti-gE antibody concentrations were determined by ELISA. Data are vaccine response rates (VRRs) and geometric mean concentrations (GMCs) and error bars indicate 95% confidence interval.CC BY · PubMed Central
Figure 3. Overall occurrence of solicited injection site reactions and general symptoms during the 7-day vaccination follow-up period (Total vaccinated cohort).
Figure 3. Overall occurrence of solicited injection site reactions and general symptoms during the 7-day vaccination follow-up period (Total vaccinated cohort).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 2

  1. Harpaz R, 2008, MMWR Recomm Rep, 57, 1
  2. Clark TG, 2005, Dev Biol (Basel), 121, 153

Cited by

See all 26

Metadata

Authors
Vink, P., Shiramoto, M., Ogawa, M., Eda, M., Douha, M., Heineman, T., & Lal, H.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • SOUSEKAI PS Clinic, Tenyamachi, Hakata-ku, Fukuoka, Japan
  • Japan Vaccine Company Ltd., Chiyoda-ku, Tokyo, Japan
  • GlaxoSmithKline (Belgium) (BE)
Corresponding author
Vink, Peter
Venue
Human Vaccines & Immunotherapeutics
Published
2016-12-09
Volume
13
Issue
3
Pages
574-578
ISSN
  • 2164-5515 (ISSN-L)
  • 2164-554X
OpenAlex
W2561886913
Cited by
26
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 6 · 2018: 7 · 2017: 1 · 2016: 1
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Human Vaccines & Immunotherapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
Keywords
varicella-zoster virus, vaccine route of administration, subcutaneous injection, intramuscular injection, immunogenicity, vaccine safety, injection site reactions, older adults, Japanese population
MeSH terms
Aged, Aged, 80 and over, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Female, Humans, Injections, Intramuscular, Injections, Subcutaneous, Japan, Male, Middle Aged, Viral Envelope Proteins, Vaccines, Subunit, Herpes Zoster Vaccine, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. https://app.cochat.ai/papers/10.1080/21645515.2016.1232787
The paper
Vink, P., Shiramoto, M., Ogawa, M., Eda, M., Douha, M., Heineman, T., & Lal, H. (2017). Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2016.1232787

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.